Last quarter (Q ), Advanced Oncotherapy's total revenue was £―, a decrease of ― from the same quarter last year. In Q, Advanced Oncotherapy's net income was £―. See Advanced Oncotherapy’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	-	-	£ 0.00	£ 0.00	£ 0.00
Cost of Revenue	-	-	-	£ 0.00	£ 1.91M	£ 0.00
Gross Profit	-	-	-	£ 0.00	£ -1.91M	£ 0.00
Operating Expense	-	£ 23.74M	£ 20.27M	£ 20.66M	£ 19.94M	£ 14.49M
Operating Income	-	£ -23.74M	£ -20.27M	£ -20.66M	£ -21.85M	£ -14.49M
Net Non Operating Interest Income Expense	-	£ 5.76M	£ 5.03M	£ -1.22M	£ -66.69K	£ -1.99M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -29.49M	£ -25.30M	£ -21.88M	£ -21.91M	£ -16.49M
Tax Provision	-	-	-	£ -1.08M	£ -759.41K	£ -2.83M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -29.49M	£ -25.30M	£ -20.79M	£ -21.15M	£ -13.66M
Basic EPS	-	£ -0.08	£ -0.09	£ -0.10	£ -0.14	£ -0.18
Diluted EPS	-	£ -0.08	£ -0.09	£ -0.10	£ -0.14	£ -0.18
Basic Average Shares	-	£ 382.48M	£ 288.98M	£ 211.48M	£ 150.54M	£ 77.83M
Diluted Average Shares	-	£ 382.48M	£ 288.98M	£ 211.48M	£ 150.54M	£ 77.83M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ -23.74M	£ -20.27M	£ 20.66M	£ 21.85M	£ 14.49M
Net Income From Continuing And Discontinued Operation	-	£ -29.49M	£ -25.30M	£ -20.79M	£ -21.15M	£ -13.66M
Normalized Income	-	£ -23.89M	£ -20.49M	£ -20.79M	£ -21.15M	£ -13.66M
Interest Expense	-	-	-	£ 1.23M	£ 80.19K	£ 1.27M
EBIT	-	£ -24.43M	£ -21.13M	£ -20.64M	£ -21.83M	£ -15.21M
EBITDA	-	£ -24.43M	£ -21.13M	£ -18.62M	£ -21.42M	£ -14.85M

Currency in GBP

Advanced Oncotherapy Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing